Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Grapefruit Juice

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    43 result(s) found for: Grapefruit Juice. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2017-001284-20 Sponsor Protocol Number: BIOGIO Start Date*: 2017-07-05
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: The effects of the proton pump inhibitor esomeprazole on the bioavailability of afatinib (Giotrif®) in patients with non-small cell lung cancer (NSCLC) 'the BIO-GIO study'
    Medical condition: Non small cell lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005784-17 Sponsor Protocol Number: REGORA Start Date*: 2016-05-19
    Sponsor Name:Erasmus MC cancer institute
    Full Title: The effects of the proton pump inhibitor esomeprazole on the bioavailability of regorafenib in patients with a metastatic colorectal cancer (mCRC) or gastrointestinal stromal tumour (GIST).
    Medical condition: GIST and mCRC patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003849-32 Sponsor Protocol Number: AGI003-007 (ARDIS-3) Start Date*: 2007-10-22
    Sponsor Name:AGI Therapeutics Research Ltd
    Full Title: An Open-label, Roll-over Safety Study of AGI-003 (Arverapamil) in the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)
    Medical condition: Irritable Bowel Syndrome with Diarrhea (IBS-D)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060845 Diarrhea predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PL (Prematurely Ended) CZ (Prematurely Ended) LT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-003265-38 Sponsor Protocol Number: PTC743-NEU-005-FA Start Date*: 2022-10-22
    Sponsor Name:PTC Therapeutics, Inc.
    Full Title: An Open-Label Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Vatiquinone in Children With Friedreich Ataxia Younger Than 7 Years of Age
    Medical condition: Friedreich Ataxia
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2017-004465-27 Sponsor Protocol Number: COCA Start Date*: 2018-02-01
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: The effects of the proton pump inhibitor esomeprazole alone or in combination with Coca-Cola on the absorption of Capecitabine in patients with colorectal cancer or other solid tumours ' the COCA s...
    Medical condition: Colorectal carcinoma or other solid tumours
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003553-82 Sponsor Protocol Number: AGI003-003 (ARDIS-1) Start Date*: 2007-10-22
    Sponsor Name:AGI Therapeutics Research Ltd
    Full Title: A Randomized, Double-blind, Placebo-controlled Study of AGI-003 (Arverapamil) in the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)
    Medical condition: Irritable Bowel Syndrome with Diarrhea (IBS-D)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060845 Diarrhea predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000276-41 Sponsor Protocol Number: SUMO Start Date*: 2020-03-05
    Sponsor Name:Erasmus MC
    Full Title: Study on the effects of an OCT2/MATE1 substrate (metformin) and inhibitor (cimetidine) on the exposure of trifluridine/tipiracil (Lonsurf®) in patients with metastatic colorectal cancer (mCRC).
    Medical condition: patients with mCRC with an indication for lonsurf treatment.
    Disease:
    Population Age: Gender:
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004008-71 Sponsor Protocol Number: ELDORADO Start Date*: 2017-01-19
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: The effect of curcumin and piperine on the pharmacokinetics of tamoxifen in patients with estrogen receptor positive breast cancer ‘the ELDORADO study’
    Medical condition: Estrogen receptor positive breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-005213-22 Sponsor Protocol Number: SUPREMES-01 Start Date*: Information not available in EudraCT
    Sponsor Name:Charite Universitätsmedizin Berlin
    Full Title: SUPREMES - Sunphenon in progressive forms of multiple sclerosis
    Medical condition: primary and secondary progressive forms of multiple sclerosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-009656-20 Sponsor Protocol Number: SUN-AK Start Date*: 2009-05-07
    Sponsor Name:Charite Universitaetsmedizin Berlin
    Full Title: Sunphenon EGCg (Epigallocatechin-Gallat) in the early stage of Alzheimer´s Disease
    Medical condition: Alzheimer´s disease (early stage)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002954-21 Sponsor Protocol Number: QBGJ398-201 Start Date*: 2020-03-31
    Sponsor Name:QED Therapeutics, Inc.
    Full Title: Phase 2, Open-Label, Dose-Escalation and Dose-Expansion Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Achondroplasia: PROPEL 2
    Medical condition: Achondroplasia in Children
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10000452 Achondroplasia LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-002550-39 Sponsor Protocol Number: PDY13949 Start Date*: 2016-10-20
    Sponsor Name:Genzyme Corporation
    Full Title: 4-part, open-label, multicenter, multinational study of the safety, tolerability, pharmacokinetics, pharmacodynamic, and exploratory efficacy of venglustat in combination with Cerezyme in adult pat...
    Medical condition: Gaucher disease
    Disease: Version SOC Term Classification Code Term Level
    24.1 10010331 - Congenital, familial and genetic disorders 10075699 Gaucher's disease type III PT
    24.1 10010331 - Congenital, familial and genetic disorders 10075697 Gaucher's disease type I PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001038-34 Sponsor Protocol Number: NK-104-305 Start Date*: 2006-02-03
    Sponsor Name:Kowa Research Europe Ltd.
    Full Title: STUDY OF PITAVASTATIN 4 MG vs. ATORVASTATIN 20 MG (FOLLOWING UP-TITRATION) IN PATIENTS WITH TYPE II DIABETES MELLITUS AND COMBINED DYSLIPIDEMIA
    Medical condition: Type II Diabetes Mellitus and Combined Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    7.1 10058110 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-003169-19 Sponsor Protocol Number: CYC-201 Start Date*: 2009-11-09
    Sponsor Name:Sigmoid Pharma Ltd
    Full Title: A Randomized, Double-blind, Placebo-controlled Study of a Controlled Release Minicapusle Formulation of Ciclosporin (CyCol™) in the Treatment of Ulcerative Colitis
    Medical condition: Ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014908-57 Sponsor Protocol Number: POA1004 Start Date*: 2009-09-03
    Sponsor Name:Purdue Pharma L.P.
    Full Title: CAPSAICIN CHALLENGE STUDY TO INVESTIGATE THE POTENTIAL ANALGESIC EFFECTS OF V113741 IN HEALTHY MALE SUBJECTS
    Medical condition: Modeling inflammatory and neuropathic pain
    Disease: Version SOC Term Classification Code Term Level
    12.0 10054095 Neuropathic pain LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-010660-42 Sponsor Protocol Number: ORA2 Start Date*: 2009-08-13
    Sponsor Name:BOWS Pharmaceuticals AG
    Full Title: A double-blind two part placebo-controlled study consisting of a single ascending and multiple-dose tolerance study of peroral insulin in patients with Type 2 diabetes
    Medical condition: Type 2 diabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020953-14 Sponsor Protocol Number: PosaBupreversion1.0 Start Date*: 2010-08-12
    Sponsor Name:Derartment of Anaesthesiology and Intensive Care, Turku University Hospital
    Full Title: Effects of posaconazole and voriconazole on the pharmacokinetics and pharmacodynamics of sublingual buprenorphine: A three-phase double-blind cross-over study in healthy subjects.
    Medical condition: - healty volunteer subjects - The study is aimed to examine the possible interactions of low-dose sublingual buprenorphine with posaconazole and voriconazole.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002461-66 Sponsor Protocol Number: CABL001A2301 Start Date*: 2017-10-09
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyro...
    Medical condition: Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10009012 Chronic myelogenous leukemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Ongoing) CZ (Ongoing) ES (Ongoing) BG (Completed) DE (Ongoing) GB (GB - no longer in EU/EEA) FR (Ongoing) NL (Ongoing) BE (Ongoing) IT (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004043-23 Sponsor Protocol Number: IDX-04B-001 Start Date*: 2013-11-13
    Sponsor Name:Idenix Pharmaceuticals Inc.
    Full Title: A Phase I/IIa Study Assessing Single and Multiple Doses of IDX21437 in Healthy and HCV-Infected Subjects
    Medical condition: Hepatitis C virus
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004848 10019751 Hepatitis C virus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001431-31 Sponsor Protocol Number: AT-01B-002 Start Date*: 2019-05-20
    Sponsor Name:Atea Pharmaceuticals, Inc.
    Full Title: A Phase 2 Study Assessing the Safety and Efficacy of AT-527 in Combination with Daclatasvir in Subjects with Chronic HCV Infection
    Medical condition: HCV-Infected subjects
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10047457 Viral hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 21:44:57 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA